Heart-Safe anesthesia: drug may tame dangerous racing pulse

NCT ID NCT01259648

Completed Symptom relief Sponsor: Centre Hospitalier Universitaire de Nīmes Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding remifentanil, a fast-acting painkiller, to standard emergency anesthesia could prevent a dangerously fast heart rate in fragile patients. 75 adults needing rapid-sequence intubation received either a low or high dose of remifentanil or a placebo. The goal was to see if it safely controls heart rate during the procedure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: remifentanil
What this could lead to: If it works, this could provide a safer way to manage heart rate during emergency anesthesia in fragile patients.
What could go wrong: This is a small, completed Phase 4 trial with only 75 participants, so results may not apply broadly. The drug may not significantly reduce tachycardia or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TACHYCARDIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Tachycardia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TACHYCARDIA

Contacts and locations

Locations

Centre Hospitalier Universitaire de Nîmes

Nîmes, Gard, 30029, France
Polyclinique Grand Sud

Nîmes, Gard, 30029, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.